Lymphoma & Plasma Cell Disorders
News
FDA approves acalabrutinib for second-line treatment of MCL
Approval was based on an 81% overall response rate in a phase 2 trial of 124 patients who had received at least one prior therapy.
News
FDA approves IV formulation of drug for CINV
The US Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of rolapitant (VARUBI®) for the same indication as the oral...
News
CCSs more likely to stay at jobs to keep health insurance
Survey results suggest childhood cancer survivors (CCSs) in the US are more likely than individuals without a history of cancer to experience “job...
News
Drug receives breakthrough designation for DLBCL
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to MOR208, an Fc-enhanced monoclonal antibody directed...
News
High symptom burden in advanced cancer patients
New research indicates that hospitalized patients with advanced cancer have a high burden of physical and psychological symptoms, and this burden...
News
EMA recommends orphan designation for G100 to treat FL
The European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products has recommended orphan designation for G100 for the treatment of...
From the Journals
Rituximab improves salvage in elderly B-cell lymphoma patients
Rituximab improved the 2-year survival rate from 20.7% to 46.8% for elderly patients with aggressive-B-cell lymphoma who relapsed after CHOP or R-...
From the Journals
Irradiation safe, effective as chemotherapy before cell transplant in mantle cell lymphoma
Total-body irradiation shown to be not only effective, but safe in autologous stem cell transplantation preparation in MCL.
News
New assay may aid diagnosis, treatment of DLBCL
A new assay may help improve the diagnosis and treatment of diffuse large B-cell lymphoma (DLBCL), according to researchers. The gene expression...
News
What we don’t know about BIA-ALCL
Results of a systematic review suggest a need for more research and long-term follow-up of patients with breast implant-associated anaplastic...
News
CAR T-cell therapy approved to treat lymphomas
The US Food and Drug Administration (FDA) has approved axicabtagene ciloleucel (Yescarta™, formerly KTE-C19) for use in adults with relapsed or...